|
Patent landscape, scope, and claims: |
Patent 9,956,188 scope and claim-by-claim analysis: eutectic of mannitol and cyclobenzaprine HCl (75%±2% / 25%±2%) and US manufacturing methods
Executive summary
- US 9,956,188 is narrowly centered on a specific eutectic composition of cyclobenzaprine HCl + mannitol defined by weight ratios (75%±2% cyclobenzaprine HCl / 25%±2% mannitol), plus dependent claims that constrain the API particle state (micronized cyclobenzaprine HCl) and manufacturing mechanics (mixing or milling, and specific process implementations like high shear granulation and roller compaction via compression).
- The core enforceable subject matter is the composition claim set (claims 1-2) and the process claim set (claims 3-9), with strongest potential leverage against competitors who manufacture, sell, or use a eutectic meeting the exact ratio and, for dependent claims, the particle size and equipment/process constraints.
- The scope is composition-ratio tight. Outside the claimed window, design-arounds can avoid literal infringement. For method claims, competitors must match the defined process steps and product outcome (the eutectic “comprises” the ratio).
- The use of the term “comprising” in the eutectic ratio and manufacturing definitions increases argument space for residuals/impurities/excipients while still requiring the ratio window; however, competitors can target ratio deviation, avoid “eutectic” characterization, or select different manufacturing routes that do not meet dependent claim limitations.
What patents cover cyclobenzaprine HCl–mannitol eutectics in the US, and how broad is the claim coverage?
Direct answer: US 9,956,188 covers (1) a cyclobenzaprine HCl/mannitol eutectic at 75%±2% / 25%±2% by weight and (2) manufacturing methods that mix or mill those components to produce that eutectic, with dependent claims adding micronized cyclobenzaprine HCl, high shear granulator milling, and roller compaction via compression.
The claim set in practice
- Composition
- Claim 1: eutectic composition with the ratio
- Claim 2: claim 1 plus micronized cyclobenzaprine HCl
- Manufacturing methods
- Claim 3: method producing the eutectic by mixing or milling cyclobenzaprine HCl with mannitol
- Claim 4: claim 3 plus milling
- Claim 5: claim 4 plus milling in a high shear granulator
- Claim 6: claim 3 plus mixing
- Claim 7: claim 6 plus mixing via compression
- Claim 8: claim 7 plus roller compaction
- Claim 9: claim 3 plus micronized cyclobenzaprine HCl
Key scope anchors (litigation-relevant)
-
Ratio window is the main gate
- Cyclobenzaprine HCl: 75%±2% → 73–77 wt%
- Mannitol: 25%±2% → 23–27 wt%
- The claims require the eutectic “comprises” the ratio by weight, so the product must meet the defined quantitative limitation.
-
The claims are defined by “eutectic”
- The scope depends on whether the manufactured blend qualifies as the claimed eutectic (not merely a physical mixture). In infringement, parties will typically fight over characterization: phase behavior, melting point depression, thermal analysis, and reproducibility. The claim language itself does not specify the characterization method.
-
Manufacturing pathway is constrained in dependent claims
- Claim 3 is broad (mixing or milling).
- Claims 5, 8 narrow to particular equipment/mode: high shear granulator; roller compaction.
What is the claim-by-claim scope of US Drug Patent 9,956,188?
Claim 1: eutectic composition with fixed wt% ratio
Plain-language scope
- A product defined as a eutectic of mannitol and cyclobenzaprine HCl.
- The eutectic is characterized by composition:
- 75%±2% cyclobenzaprine HCl
- 25%±2% mannitol
- by weight
Litigation leverage
- This is a composition claim. If a competitor sells or uses the same eutectic meeting the ratio, infringement is primarily about:
- whether their material is the claimed eutectic, and
- whether it fits within the wt% boundaries.
Design-around lines
- Move outside the ratio (e.g., 70/30, 80/20, or even 72/28 if outside 75±2 and 25±2).
- Avoid producing a material that would be deemed “the eutectic” at the claimed composition.
Claim 2: micronized cyclobenzaprine HCl within the eutectic
Plain-language scope
- Claim 1 plus the cyclobenzaprine HCl must be micronized.
Scope sensitivity
- The claim does not define a micron size cut-off. In practice, infringement disputes likely turn on:
- particle size distributions,
- sieve analysis or laser diffraction,
- and what constitutes “micronized” in the relevant technical context.
Design-around
- Use non-micronized cyclobenzaprine HCl or a particle size distribution outside whatever standard the claimant uses to label “micronized.”
Claim 3: method producing the eutectic via mixing or milling
Plain-language scope
- A method of manufacturing the eutectic of claim 1.
- The method comprises:
- mixing cyclobenzaprine HCl and mannitol OR
- milling cyclobenzaprine HCl and mannitol
- The eutectic produced must comprise:
- 75%±2% cyclobenzaprine HCl
- 25%±2% mannitol (by weight)
Scope effect of “comprising”
- “Method … wherein the eutectic comprises 75%±2% … and 25%±2% … by weight” means the eutectic must contain those proportions. It does not explicitly exclude trace impurities or other components, but the ratio constraint is still mandatory.
Litigation leverage
- Claim 3 is a process claim that is broad on steps but tight on product outcome.
Design-around
- Avoid making the product meeting the eutectic ratio.
- Use a manufacturing method that does not include “mixing” or “milling” as those terms are construed (though most blending/processing could be argued as “mixing,” so practical design-arounds usually focus on ratio and characterization).
Claim 4: milling method
Plain-language scope
- Claim 3 plus the method comprises milling cyclobenzaprine HCl and mannitol.
Difference from claim 3
- Removes the “mixing” alternative. A competitor who only mixes (no milling) can avoid claim 4.
Claim 5: high shear granulator milling
Plain-language scope
- Claim 4 plus milling occurs in a high shear granulator.
This is a strong narrowing feature
- Even if a competitor mills, the equipment matters for literal infringement.
Design-around
- Mill in a different apparatus (e.g., ball mill, jet mill, rotor-stator without high shear granulation, or other equipment). If they still produce the claimed eutectic, claim 3 or claim 4 may remain in play, but claim 5 could be avoided.
Claim 6: mixing method (no milling)
Plain-language scope
- Claim 3 plus the method comprises mixing cyclobenzaprine HCl and mannitol.
Difference from claim 4
- Claim 6 removes milling as the method step.
Claim 7: mixing via compression
Plain-language scope
- Claim 6 plus mixing “via compression.”
Interpretation pressure
- “Mixed via compression” reads like a process where compression is used to create the eutectic structure (not just tablet compaction for a final dosage form). This can become a claim-construction battleground.
Design-around
- Use mixing that does not employ compression as the mixing mechanism.
Claim 8: roller compaction
Plain-language scope
- Claim 7 plus compression via roller compaction.
High-value narrowing
- Roller compaction is specific. Competitors using slugging, fluid bed granulation, or direct blending without roller compaction are positioned to avoid claim 8 while still potentially infringing claim 3 (if they make the same eutectic by mixing/milling).
Claim 9: micronized cyclobenzaprine HCl in the method
Plain-language scope
- Claim 3 plus cyclobenzaprine HCl is micronized.
Potential overlap
- If a competitor’s method uses micronized API and makes the eutectic ratio, claim 9 could be triggered regardless of whether they mix or mill.
How do these claims interact with each other, and what does that mean for enforcement risk?
Independent vs dependent claim structure
- Independent claim: Claim 1 is independent composition.
- Independent claim (process): Claim 3 is independent manufacturing method.
- Dependent claims add constraints:
- Claim 2 and 9 constrain micronization
- Claims 4-5 constrain milling and then high shear granulator
- Claims 6-8 constrain mixing, then compression, then roller compaction
Practical infringement pathways
- Composition infringement scenario
- Product made or sold that is the claimed eutectic ratio.
- Process infringement scenario
- Manufacturing step includes mixing/milling that results in the claimed eutectic ratio.
- If their process uses micronized cyclobenzaprine HCl, the micronization-dependent claims add further constraints for additional coverage.
Biggest vulnerability: ratio and characterization
- The clearest design-around is ratio deviation.
- The second is challenging whether the product is truly a eutectic versus a physical blend. The claims do not define testing protocols, but infringement usually turns on scientific evidence.
What formulations are protected by US 9,956,188, and does it cover tablets/capsules?
Direct answer: US 9,956,188 is written as a eutectic composition and manufacturing method. It does not claim a finished dosage form (tablet, capsule, film, etc.) in the claim text provided. Its protection most directly targets the intermediate eutectic and how it is produced.
Likely scope boundaries
- If a finished dosage form uses the claimed eutectic intermediate meeting the ratio, a composition claim can still be asserted, but the claim language itself does not explicitly add dosage-form elements.
- Competitors formulating final products could still face exposure if they purchase or produce the patented eutectic as a material ingredient.
When does the eutectic patent lose exclusivity, and what term issues control?
No answer can be produced here from the claim text alone. A correct exclusivity/expiration analysis requires the patent’s filing date, priority, issuance date, status (active/expired/terminally disclaimed), and any regulatory exclusivity tie-ins. Without those data, an expiration timeline would be incomplete.
What patent landscape surrounds this eutectic, and how many “design-around” opportunities exist?
No complete landscape count can be produced from the claim text alone because a landscape requires:
- full bibliographic data for US 9,956,188 (assignee, priority, CPCs),
- citation sets (forward/backward),
- family members and related jurisdictions,
- and the Orange Book and PCT/WO coverage for cyclobenzaprine HCl formulations.
That said, the internal architecture of US 9,956,188 suggests three principal design-around vectors:
1) Ratio shift
- Move outside 73–77 wt% cyclobenzaprine HCl and 23–27 wt% mannitol.
2) Avoid micronization-dependent pathways
- If using API milling that changes the particle size distribution, ensure it does not meet whatever standard “micronized” is argued to mean.
3) Avoid specific equipment/process limitations for dependent claims
- For claim 5: avoid high shear granulator.
- For claim 8: avoid roller compaction via compression.
If a competitor shifts ratio, they can avoid claim 1 and, by extension, avoid the product-outcome requirement in claim 3. If they do not shift ratio, but adjust equipment, they may still face claim 3/1 exposure.
What patent litigation, Paragraph IV challenges, or Orange Book status relate to US 9,956,188?
No complete litigation or regulatory status analysis can be produced from the claim text alone. An accurate assessment requires:
- the Orange Book listings for cyclobenzaprine products implicated by this eutectic,
- the FDA application numbers (ANDA/NDA),
- and litigation docket identifiers tied to this patent.
Key takeaways
- US 9,956,188 is a tight composition and manufacturing process patent centered on a cyclobenzaprine HCl/mannitol eutectic at 75%±2% / 25%±2% by weight.
- The strongest claim anchors are claim 1 (composition) and claim 3 (method producing the eutectic); dependent claims add constraints on micronization (claims 2, 9), milling (claim 4), high shear granulator (claim 5), and roller compaction via compression (claim 8).
- Design-around emphasis is on:
- ratio deviation outside the wt% windows,
- avoiding micronization, and
- changing equipment/process to avoid dependent limitations.
- The claim language you provided does not explicitly extend to final dosage forms; its protection targets the eutectic intermediate and its manufacture.
FAQs
1) Does US 9,956,188 require micronized cyclobenzaprine HCl to infringe?
Not for independent coverage. Claim 1 and claim 3 do not require micronization. Micronization is required only for claims 2 and 9.
2) If a competitor mills cyclobenzaprine HCl and mannitol but in a ball mill, do they avoid claim 5?
Claim 5 is limited to milling in a high shear granulator. A ball mill can avoid claim 5, but the competitor can still risk claim 4 and claim 3 if they make the claimed eutectic ratio.
3) Can a competitor avoid infringement by roller compacting after forming the eutectic?
Claim 8 targets “mixing via compression” and then roller compaction as part of the method leading to the eutectic. If roller compaction occurs as a separate step after the eutectic is already formed by a different route, that can affect claim mapping, but the product-outcome requirement in claim 3 still matters.
4) Does “eutectic comprises” allow other components besides the two-actives?
The ratio limits must be met. The claims do not explicitly bar other constituents, but they require the eutectic to include the specified proportion of cyclobenzaprine HCl and mannitol by weight.
5) Is making any cyclobenzaprine HCl/mannitol blend infringing?
No, the claims require the material be a eutectic at the specific ratio window. A physical mixture at a different ratio is not within the literal claim language you provided.
References
No sources were provided or extracted in the prompt beyond the claim text.
More… ↓
⤷ Start Trial
|
